Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

TTD Drug ID: DCL000342

Drug Information
NameSU-6668    
CompanyPfizer / Sugen    
IndicationAdvanced solid tumoursDiscontinued    
Therapeutic ClassAntineoplastic Agents    
ClinicalTrials.govNCT00024206;    
TargetPlatelet-derived growth factor receptorMultitarget[1][2]
Aurora BMultitarget[1][2]
Basic fibroblast growth factor receptor 1 Multitarget[1][2]
Platelet-derived growth factor receptorInhibitor[1][2]
Basic fibroblast growth factor receptor 1 Inhibitor[1][2]
Aurora BInhibitor[1][2]
Vascular endothelial growth factor receptor 2Inhibitor[1][2]
Aurora AInhibitor[1][2]
Aurora AMultitarget[1][2]
Vascular endothelial growth factor receptor 2Multitarget[1][2]
Ref 1A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. To Reference
Ref 2Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies. Clin Cancer Res. 2005 Sep 1;11(17):6240-6. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543